An Exploratory Application of Multilayer Networks and Pathway Analysis in Pharmacogenomics

被引:3
|
作者
Milano, Marianna [1 ,2 ]
Agapito, Giuseppe [2 ,3 ]
Cannataro, Mario [2 ,4 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Data Analyt Res Ctr, I-88100 Catanzaro, Italy
[3] Magna Graecia Univ Catanzaro, Dept Law Econ & Social Sci, I-88100 Catanzaro, Italy
[4] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, I-88100 Catanzaro, Italy
关键词
pharmacogenomics; network analysis; multilayer networks; community detection; pathway enrichment analysis; PROTEIN-PROTEIN INTERACTION; DRUG; IDENTIFICATION;
D O I
10.3390/genes14101915
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Over the years, network analysis has become a promising strategy for analysing complex system, i.e., systems composed of a large number of interacting elements. In particular, multilayer networks have emerged as a powerful framework for modelling and analysing complex systems with multiple types of interactions. Network analysis can be applied to pharmacogenomics to gain insights into the interactions between genes, drugs, and diseases. By integrating network analysis techniques with pharmacogenomic data, the goal consists of uncovering complex relationships and identifying key genes to use in pathway enrichment analysis to figure out biological pathways involved in drug response and adverse reactions. In this study, we modelled omics, disease, and drug data together through multilayer network representation. Then, we mined the multilayer network with a community detection algorithm to obtain the top communities. After that, we used the identified list of genes from the communities to perform pathway enrichment analysis (PEA) to figure out the biological function affected by the selected genes. The results show that the genes forming the top community have multiple roles through different pathways.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Application of Multilayer Network Models in Bioinformatics
    Lv, Yuanyuan
    Huang, Shan
    Zhang, Tianjiao
    Gao, Bo
    FRONTIERS IN GENETICS, 2021, 12
  • [32] Application of DNA Microarrays in pharmacogenomics and toxicogenomics
    Chin, KV
    Kong, ANT
    PHARMACEUTICAL RESEARCH, 2002, 19 (12) : 1773 - 1778
  • [33] A survey of community detection methods in multilayer networks
    Huang, Xinyu
    Chen, Dongming
    Ren, Tao
    Wang, Dongqi
    DATA MINING AND KNOWLEDGE DISCOVERY, 2021, 35 (01) : 1 - 45
  • [34] Dynamic Evolution Analysis of Digital Technology Multilayer Convergence Networks
    Wang, Qianying
    Liu, Tingli
    Huang, Tingyang
    Tian, Qingqing
    SYSTEMS, 2024, 12 (10):
  • [35] Using text to build semantic networks for pharmacogenomics
    Coulet, Adrien
    Shah, Nigam H.
    Garten, Yael
    Musen, Mark
    Altman, Russ B.
    JOURNAL OF BIOMEDICAL INFORMATICS, 2010, 43 (06) : 1009 - 1019
  • [36] Controllability of multilayer networks
    Jiang, Lixin
    Tang, Longkun
    Lu, Jinhu
    ASIAN JOURNAL OF CONTROL, 2022, 24 (04) : 1517 - 1527
  • [37] Graphlets in multilayer networks
    Sallmen, Sallamari
    Nurmi, Tarmo
    Kivela, Mikko
    JOURNAL OF COMPLEX NETWORKS, 2021, 10 (02)
  • [38] Clinical Application and Evaluation of Pharmacogenomics in Tumor Chemotherapy
    Feng Jifeng
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2014, 2 (01): : 278 - 281
  • [39] Opinion, experience and educational preferences concerning pharmacogenomics: an exploratory study of Quebec pharmacists
    Meloche, Maxime
    Kwon, Hyuk J.
    Letarte, Nathalie
    Bussieres, Jean-Francois
    Vadnais, Barbara
    Hurlimann, Thierry
    Lavoie, Annie
    Beauchesne, Marie-France
    de Denus, Simon
    PHARMACOGENOMICS, 2020, 21 (04) : 235 - 245
  • [40] Application of the DruGeVar Database in Cancer Genomics and Pharmacogenomics
    Sarris, Konstantinos
    Komianou, Angeliki
    Patrinos, George P.
    Katsila, Theodora
    PUBLIC HEALTH GENOMICS, 2017, 20 (02) : 142 - 147